Ocular Adverse Events With Semaglutide

Does semaglutide increase the risk of ocular adverse events?In this systematic review and meta-analysis of randomized clinical trials, semaglutide was not associated with higher risk of ocular adverse events, including diabetic retinopathy. However, it was associated with nonarteritic anterior ischemic optic neuropathy (NAION).Future studies should implement standardized methods for assessing ocular adverse events to clarify the potential association of semaglutide with NAION.

Corresponding Author: Fernando Gerchman, MD, PhD, Division of Endocrinology and Metabolism, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos 2350, 4th Floor, Room 401, 90035-903 Porto Alegre, Rio Grande do Sul, Brazil (fgerchman@hcpa.edu.br).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.